A Need for Reorganization of the Food and Drug Administration

被引:0
作者
Edlich, Richard F. [1 ]
Mason, Shelley S. [2 ]
Reddig, Jill S. [2 ]
Gubler, K. Dean [3 ]
Long, William B., III
机构
[1] Univ Virginia Hlth Syst, Charlottesville, VA USA
[2] Multiple Sclerosis Res Fund, Brush Prairie, WA USA
[3] Legacy Emanuel Hosp, Legacy Verified Level Shock Trauma Ctr Pediat & A, Trauma Specialists LLP, Portland, OR USA
关键词
Food and Drug Administration; Center for Devices and Radiological Health; citizen's petition; Grassley-Dodd bill; Government Accountability Office; Food and Drug Administration Safety Act of 2007;
D O I
10.1615/JEnvironPatholToxicolOncol.v29.i2.10
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The associate director for science and medicine in the Office of Drug Safety at the Food and Drug Administration (FDA), Dr. David Graham, reported that the FDA was incapable of protecting Americans from unsafe drugs. In testimony to the Senate Finance Committee, he stated that the FDA has let the American people down and betrayed public trust. Drastic changes and measures within the FDA must be made to ensure the safety of American consumers of drugs, products, and medical devices. Efforts such as the introduction of the Grassley-Dodd Bill, allowing the FDA to order immediate drug recall or increased risk warnings, followed by the FDA Safety Act of 2007, are still not enough to ensure the safety and efficacy of drugs, biological products, and medical devices that the American public use every day. In this report, we describe past and present efforts by congressional leaders, FDA representatives, and American citizens to effect changes within the FDA in order to protect America from unsafe drugs and medical devices. We describe our own struggles in passing a citizen's petition to ban cornstarch in medical gloves, and the lack of response and responsibility that the FDA has displayed.
引用
收藏
页码:81 / 84
页数:4
相关论文
共 50 条
  • [21] Texas pharmacists' knowledge of reporting serious adverse drug events to the Food and Drug Administration
    Gavaza, Paul
    Brown, Carolyn M.
    Lawson, Kenneth A.
    Rascati, Karen L.
    Wilson, James P.
    Steinhardt, Mary
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2011, 51 (03) : 397 - U135
  • [22] The Food and Drug Administration and pragmatic clinical trials of marketed medical products
    Anderson, Monique L.
    Griffin, Joseph
    Goldkind, Sara F.
    Zeitler, Emily P.
    Wing, Liz
    Al-Khatib, Sana M.
    Sherman, Rachel E.
    CLINICAL TRIALS, 2015, 12 (05) : 511 - 519
  • [23] Food and drug administration approval process for dermatology drugs in the United States
    Boozalis, Emily
    Semenov, Yevgeniy R.
    Kwatra, Shawn G.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (06) : 536 - 538
  • [25] The Nutrition Facts Label - U.S. Food and Drug Administration
    Beckwell, Jillian
    JOURNAL OF CONSUMER HEALTH ON THE INTERNET, 2025, 29 (01) : 86 - 100
  • [26] Black box 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk
    Murphy, S
    Roberts, R
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (01) : 34 - 39
  • [27] Computational modeling of the Food and Drug Administration's benchmark centrifugal blood pump
    Good, Bryan C.
    Manning, Keefe B.
    ARTIFICIAL ORGANS, 2020, 44 (07) : E263 - E276
  • [28] Concepts in US Food and Drug Administration Regulation of Artificial Intelligence for Medical Imaging
    Kohli, Ajay
    Mahajan, Vidur
    Seals, Kevin
    Kohli, Ajit
    Jha, Saurabh
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (04) : 886 - 888
  • [29] Review of red yeast rice content and current Food and Drug Administration oversight
    Childress, Lindsey
    Gay, Andrea
    Zargar, Atanaz
    Ito, Matthew K.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (02) : 117 - 122
  • [30] Evaluation of a Food and Drug Administration Mandate to Limit Acetaminophen in Prescription Combination Products
    Goldberger D.
    Vearrier D.
    Journal of Medical Toxicology, 2017, 13 (4) : 303 - 308